02 July 2014

Norgine today announced that Peter Martin has been elected as a member of the executive board of EUCOPE for a period of three years. Peter Martin’s appointment takes effect immediately.

As a member of the executive board, Peter Martin will actively help shape EUCOPE’s mandate as an organisation focusing on key EU regulatory developments.

Peter Martin says: “I am looking forward to working as a EUCOPE executive board member as this is a significant time of change for the pharmaceutical sector in Europe. Mid-sized pharmaceutical companies are facing some challenging yet exciting times as we look to improve access to medicines that can improve patients’ lives.”


Notes to Editors

Peter Martin – biographical details
Peter Martin joined Norgine in 2004. Peter has worked in a variety of sales, marketing, research and development and general  management roles in the pharmaceutical industry in Europe and the US for the past twenty-six years. He has always been keenly interested in the interface between the healthcare industry, patients’ associations and the individual patient.
Peter has an MA in Chemistry from Oxford University and an MBA from the Open University.

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) was founded in autumn 2008 to promote companies and associations active in research, development, production and distribution of pharmaceutical products and enhance their scientific, technical, economic and legal objectives. Via the German Pharmaceutical Industry Association BPI with 270 member companies and the UK pharma association EMIG with 170 member companies as well as via BioDeutschland with 275 highly innovative biotech companies as well as the Swedish Association for mid-sized pharmaceutical companies IML and SwedenBIO, EUCOPE represents more than 900 member companies, many of them mid-sized companies and SMEs. In addition, many innovative companies from Sweden, UK, France, Bulgaria, Italy, Greece, Germany, the Netherlands and Austria are represented on the board of the association.

About Norgine
Norgine is a leading independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people.

Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology , critical and supportive care. Norgine owns a manufacturing and development site in Hengoed, UK and a manufacturing site in Dreux, France.
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US.
For more information, please visit

NORGINE and the sail logo are trademarks of the Norgine group of companies.

Media Enquiries
Norgine: Charlotte Andrews, Norgine Corporate Communications, +44 (0)1895 453607
EUCOPE: Cornelie Terlez, +32 (0)2 2821070, +32 (0)471 01 65 55